DNA methylation is frequently described as a 'silencing' epigenetic mark, and indeed this function of 5-methylcytosine was originally proposed in the 1970s. Now, thanks to improved genome-scale mapping of methylation, we can evaluate DNA methylation in different genomic contexts: transcriptional start sites with or without CpG islands, in gene bodies, at regulatory elements and at repeat sequences. The emerging picture is that the function of DNA methylation seems to vary with context, and the relationship between DNA methylation and transcription is more nuanced than we realized at first. Improving our understanding of the functions of DNA methylation is necessary for interpreting changes in this mark that are observed in diseases such as cancer.

Functions of DNA methylation: islands, start sites, gene bodies and beyond

The reference human genome sequence set the stage for studies of genetic variation and its association with human disease, but epigenomic studies lack a similar reference. To address this need, the NIH Roadmap Epigenomics Consortium generated the largest collection so far of human epigenomes for primary cells and tissues. Here we describe the integrative analysis of 111 reference human epigenomes generated as part of the programme, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression. We establish global maps of regulatory elements, define regulatory modules of coordinated activity, and their likely activators and repressors. We show that disease- and trait-associated genetic variants are enriched in tissue-specific epigenomic marks, revealing biologically relevant cell types for diverse human traits, and providing a resource for interpreting the molecular basis of human disease. Our results demonstrate the central role of epigenomic information for understanding gene regulation, cellular differentiation and human disease.

Integrative analysis of 111 reference human epigenomes

Polycomb group proteins maintain the gene-expression pattern of different cells that is set during early development by regulating chromatin structure. In mammals, two main Polycomb group complexes exist — Polycomb repressive complex 1 (PRC1) and 2 (PRC2). PRC1 compacts chromatin and catalyses the monoubiquitylation of histone H2A. PRC2 also contributes to chromatin compaction, and catalyses the methylation of histone H3 at lysine 27. PRC2 is involved in various biological processes, including differentiation, maintaining cell identity and proliferation, and stem-cell plasticity. Recent studies of PRC2 have expanded our perspectives on its function and regulation, and uncovered a role for non-coding RNA in the recruitment of PRC2 to target genes.

/pdf/the-polycomb-complex-prc2-and-its-mark-in-life-42bk8re8dn.pdf

The Polycomb complex PRC2 and its mark in life

The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.

http://sdjohnston.faculty.noctrl.edu/360/Cancer%20Epigenome.pdf

A decade of exploring the cancer epigenome — biological and translational implications

Stem cells are defined as cells able to both extensively self-renew and differentiate into progenitors. Research data show that more resistant stem cells than common cancer cells exist in cancer patients.To identify unrecognized differences between cancer stem cells and cancer cells might be able to develope effective classification,diagnose and treat ment for cancer.

Stem Cells,Cancer and Cancer Stem Cells

The cancer stem cell (CSC) model suggests that a subpopulation of cells within the tumor, the CSCs, is responsible for cancer relapse and metastasis formation. CSCs hold unique characteristics, such as self-renewal, differentiation abilities, and resistance to chemotherapy, raising the need for discovering drugs that target CSCs. Previously we have found that the antihypertensive drug spironolactone impairs DNA damage response in cancer cells. Here we show that spironolactone, apart from inhibiting cancerous cell growth, is also highly toxic to CSCs. Notably, we demonstrate that CSCs have high basal levels of DNA double-strand breaks (DSBs). Mechanistically, we reveal that spironolactone does not damage the DNA but impairs DSB repair and induces apoptosis in cancer cells and CSCs while sparing healthy cells. In vivo, spironolactone treatment reduced the size and CSC content of tumors. Overall, we suggest spironolactone as an anticancer reagent, toxic to both cancer cells and, particularly to, CSCs.

Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response

1. Early Embryonic Cell Fate Decisions in the Mouse Yojiro Yamanaka and Amy Ralston Abstract Introduction Lineage Establishment and the Pre?stem Cell Program: Formation of the Blastocyst Lineage Maintenance and the Stem Cell Program: Beyond the Blastocyst The Second Lineage Decision: Subdividing the ICM Cell Signaling Regulates PE/EPI Specification Establishment and Modulation of Pluripotency in the EPI Lineage Conclusion 2. Nuclear Architecture in Stem Cells Kelly J. Morris, Mita Chotalia and Ana Pombo Abstract Introduction Functional Compartmentalization of the ES Cell Nucleus Stem Cell Features of Other Nucleoplasmic Subcompartments Chromatin Features Characteristic of ES Cell Nuclei Conclusion 3. Epigenetic Regulation of Pluripotency Eleni M. Tomazou and Alexander Meissner Abstract Introduction Epigenetic Modifications The Epigenome of ES Cells Conclusion 4. Autosomal Lyonization of Replication Domains During Early Mammalian Development Ichiro Hiratani and David M. Gilbert Abstract Introduction Replication Timing Program: An Elusive Measure of Genome Organization An Evolutionarily Conserved Epigenetic Fingerprint Replication Timing as a Quantitative Index of 3?Dimensional Genome Organization Replication Timing Reveals An Epigenetic Transition: Autosomal Lyonization at the Epiblast Stage Replication Timing and Cellular Reprogramming: Further Support for Autosomal Lyonization Maintenance and Alteration of Replication Timing Program and Its Potential Roles Conclusion 5. PRESERVATION OF GENOMIC INTEGRITY IN MOUSE EMBRYONIC STEM CELLS Peter J. Stambrook and Elisia D. Tichy Abstract Introduction and Historical Perspective Mutation Frequencies in Somatic Cells Protection of the Mouse ES Cell Genome Conclusion 6. Transcriptional Regulation in Embryonic Stem Cells Jian?Chien Dominic Heng and Huck?Hui Ng Abstract Introduction Embryonic Stem Cells as a Model to Study Transcriptional Regulation Transcription Factors Governing ESC Pluripotency TranscriptionalRegulatory Network Technologies for Dissecting the Transcriptional Regulatory Network The Core Transcriptional Regulatory Network: Oct4, Sox2 and Nanog Expanded Transcriptional Regulatory Network Enhanceosomes: Transcription Factor Complex Integration of Signaling Pathways to Transcriptional Network Interface Between Transcriptional and Epigenetic Regulation Conclusion 7. ALTERNATIVE SPLICING IN STEM CELL SELF?RENEWAL AND DIFERENTIATION David A. Nelles and Gene W. Yeo Abstract Introduction Introduction to Alternative Splicing Alternative Splicing of Genes Implicated in Stemness and Differentiation Genome?Wide Methods to Identify and Detect Alternative Splicing Events Regulation of Alternative Splicing by RNA Binding Proteins Conclusion and Perspectives 8. MicroRNA Regulation of Embryonic Stem Cell Self?Renewal and Differentiation Collin Melton and Robert Blelloch Abstract Introduction: The Self?Renewal Program Embryonic Stem Cells miRNA Biogenesis and Function ESCC miRNAs Promote Self?Renewal miRNAs Induced during ESC Differentiation Suppress the Self?Renewal Program Regulatory Networks Controlling miRNA Expression miRNAs Can Promote or Inhibit Dedifferentiation to iPS Cells miRNAs in Somatic Stem Cells miRNAs in Cancer Cells Conclusion 9. TELOMERES AND TELOMERASE IN ADULT STEM CELLS and PLURIPOTENT EMBRYONIC STEM CELLS Rosa M. Marion and Maria A. Blasco Abstract Introduction Regulation of Telomeres and Telomerase Role of Telomeres and Telomerase in Adult SC Compartments Telomeres and Telomerase Regulation During Reprogramming by SCNT Telomeres and Telomerase Regulation During iPS Cell Generation Telomerase Activation is Essential for the "Good" Quality of the Resulting iPS Cells Regulation of Telomere Reprogramming Conclusion 10. X Chromosome Inactivation and Embryonic Stem Cells Tahsin Stefan Barakat and Joost Gribnau Abstract Introduction Cis Acting Factors in XCI Trans Acting Factors in XCI Counting and Choice Silencing and Maintenance of

The cell biology of stem cells

Embryonic stem cells (ESCs) are regulated by pluripotency-related transcription factors in concert with chromatin regulators. To identify additional stem cell regulators, we screened a library of endogenously labeled fluorescent fusion proteins in mouse ESCs for fluorescence loss during differentiation. We identified SET, which displayed a rapid isoform shift during early differentiation from the predominant isoform in ESCs, SETα, to the primary isoform in differentiated cells, SETβ, through alternative promoters. SETα is selectively bound and regulated by pluripotency factors. SET depletion causes proliferation slowdown and perturbed neuronal differentiation in vitro and developmental arrest in vivo, and photobleaching methods demonstrate SET's role in maintaining a dynamic chromatin state in ESCs. This work identifies an important regulator of pluripotency and early differentiation, which is controlled by alternative promoter usage.

https://dr.ntu.edu.sg/bitstream/10356/86534/1/Alternative%20SET-TAFI%20Promoters%20Regulate%20Embryonic%20Stem%20Cell%20Differentiation.pdf

Alternative SET/TAFI Promoters Regulate Embryonic Stem Cell Differentiation

Tumor-initiating cells are a subpopulation of cells that have self-renewal capacity to regenerate a tumor. Here, we identify stem cell-like chromatin features in human glioblastoma initiating cells (GICs) and link them to a loss of the repressive histone H3 lysine 9 trimethylation (H3K9me3) mark. Increasing H3K9me3 levels by histone demethylase inhibition led to cell death in GICs but not in their differentiated counterparts. The induction of apoptosis was accompanied by a loss of the activating H3 lysine 9 acetylation (H3K9ac) modification and accumulation of DNA damage and downregulation of DNA damage response genes. Upon knockdown of histone demethylases, KDM4C and KDM7A both differentiation and DNA damage were induced. Thus, the H3K9me3-H3K9ac equilibrium is crucial for GIC viability and represents a chromatin feature that can be exploited to specifically target this tumor subpopulation.

Eran Meshorer

Papers

Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response

The cell biology of stem cells

Alternative SET/TAFI Promoters Regulate Embryonic Stem Cell Differentiation

Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation

Promiscuous global transcription in pluripotent embryonic stem cells